Comparison Of The Clinical Efficacy And Safety Of SOX And XELOX In Advanced Gastric Cancer

Objective To compare the clinical efficacy and safety between the SOX program and XELOX program in the first-line chemotherapy in the patients with advanced gasric cancer.Methods In this study,62 patients with primary advanced gastric cancer were retrospectively analyzed.All cases were confirmed to be gastric cancer by pathology and imaging features,including patients who were unable to surgical resection and had multiple metastases for the first visit.The cases were firstly treated with systemic chemotherapy in the oncology department of the First Affiliated Hospital of University of Soochow University from April 2014 to February 2016.Systemic chemotherapy were necessary in the patients who were diagnosed as advanced gastric cancer,to ease symptoms,relieve pain,improve quality of life and prolong the survival time.62 cases of advanced gastric cancer were divided into group A(n=28)and group B(n=34).Group A was received SOX regimen,while group B was given with XELOX regimen.The short-term efficacy,total effective rate,adverse reaction rate and median survival time,life quality were compared two groups.Results These patients were followed up.It had no significant difference in short-term efficacy between the two groups.Compared with the effective rate of the two groups,the difference was not significant(p> 0.05).In long-term efficacy,the median time to progression(TTP)and overall survival(OS)of group A were inferior to group B,but the difference was not statistically significant.The primary adverse reactions were myelosuppression,gastrointestinal reactions,hepatic function damage,peripheral nerve toxicity and hand-foot syndrome.The incidence of mye Iosuppression in SOX group was higher than XELOX group in the hematological toxicity,which was not statistically significant(p>0.05).The incidence of hand-foot syndromes(38.2%vs10.7%)was higher in group B than that in group A(P=0.003,p<0.05).The incidence of it below grade III was also similar to the above incidence,which had statistical significance(P=0.000,p<0.05).The rate of oral mucositis and diarrhea was also higher in group B than group A,while the rate in nausea,peripheral neurotoxicity and liver function damage was lower than that in group A.But it was no statistically significant.After treatment with different postoperative first-line chemotherapy regimens,the KPS score showed no difference.Conclusion There was equivalent in the efficacy of SOX regimen and XELOX regimen as first-line chemotherapeutic regimen for advanced gastric cancer.The adverse reaction of two groups were tolerated and resolved by symptomatic treatment.Bone marrow suppression occur more commonly in SOX group in comparison with XELOX group,while hand-foot syndromes was obviously observed in XELOX group.When patients in XELOX regimen cannot tolerate adverse reaction of hand-foot syndromes,we can choose SOX regimen.We can choose the appropriate chemotherapy regimen according to the patient’s condition.